These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8662780)

  • 1. Contribution of arginine residues in the RP135 peptide derived from the V3 loop of gp120 to its interaction with the Fv fragment of the 0.5beta HIV-1 neutralizing antibody.
    Faiman GA; Levy R; Anglister J; Horovitz A
    J Biol Chem; 1996 Jun; 271(23):13829-33. PubMed ID: 8662780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model of a gp120 V3 peptide in complex with an HIV-neutralizing antibody based on NMR and mutant cycle-derived constraints.
    Zvi A; Tugarinov V; Faiman GA; Horovitz A; Anglister J
    Eur J Biochem; 2000 Feb; 267(3):767-79. PubMed ID: 10651813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding.
    Tugarinov V; Zvi A; Levy R; Hayek Y; Matsushita S; Anglister J
    Structure; 2000 Apr; 8(4):385-95. PubMed ID: 10801487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.
    Kirby KA; Ong YT; Hachiya A; Laughlin TG; Chiang LA; Pan Y; Moran JL; Marchand B; Singh K; Gallazzi F; Quinn TP; Yoshimura K; Murakami T; Matsushita S; Sarafianos SG
    FASEB J; 2015 Jan; 29(1):70-80. PubMed ID: 25351987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
    Zvi A; Feigelson DJ; Hayek Y; Anglister J
    Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thermodynamic analysis of the interaction between the 0.5beta Fv fragment and the RP135 peptide antigen derived from the V3 loop of HIV-1 gp120.
    Faiman GA; Horovitz A
    J Biol Chem; 1997 Dec; 272(50):31407-11. PubMed ID: 9395472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of the principal neutralization site of HIV-1.
    Ghiara JB; Stura EA; Stanfield RL; Profy AT; Wilson IA
    Science; 1994 Apr; 264(5155):82-5. PubMed ID: 7511253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135.
    Huang X; Barchi JJ; Lung FD; Roller PP; Nara PL; Muschik J; Garrity RR
    Biochemistry; 1997 Sep; 36(36):10846-56. PubMed ID: 9312273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.
    Rosen O; Chill J; Sharon M; Kessler N; Mester B; Zolla-Pazner S; Anglister J
    Biochemistry; 2005 May; 44(19):7250-8. PubMed ID: 15882063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing hydrogen bonds in the antibody-bound HIV-1 gp120 V3 loop by solid state NMR REDOR measurements.
    Balbach JJ; Yang J; Weliky DP; Steinbach PJ; Tugarinov V; Anglister J; Tycko R
    J Biomol NMR; 2000 Apr; 16(4):313-27. PubMed ID: 10826883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1.
    Inouye P; Cherry E; Hsu M; Zolla-Pazner S; Wainberg MA
    AIDS Res Hum Retroviruses; 1998 Jun; 14(9):735-40. PubMed ID: 9643373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cis proline turn linking two beta-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide.
    Tugarinov V; Zvi A; Levy R; Anglister J
    Nat Struct Biol; 1999 Apr; 6(4):331-5. PubMed ID: 10201400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
    Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
    J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.
    Pantophlet R; Aguilar-Sino RO; Wrin T; Cavacini LA; Burton DR
    Virology; 2007 Aug; 364(2):441-53. PubMed ID: 17418361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
    Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
    PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.